Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi GU1: ivonescimab + enfortumab vedotin versus pembrolizumab + enfortumab vedotin in untreated advanced urothelial carcinoma
2026-525831-17-00Phase 3Authorised
- Sponsor
- Summit Therapeutics
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Ivonescimab + enfortumab vedotin with Pembrolizumab + enfortumab vedotin (2 arms). Primary endpoints: Adverse events, Laboratory abnormalities and 4 more. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2026-525831-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525831-17-00.